PEG-glutaminase/diazo-oxo-L-norleucine

Drug Profile

PEG-glutaminase/diazo-oxo-L-norleucine

Alternative Names: Diazo-oxo-L-norleucine/PEG-glutaminase; Diazooxonorleucine/PEG-glutaminase; DON/PEG-PGA; GlutaDON; PEG-glutaminase/diazooxonorleucine; PEG-PGA/DON

Latest Information Update: 16 Jun 2015

Price : $50

At a glance

  • Originator New Medical Enzymes AG
  • Class Antineoplastics; Azo compounds; Glutaminase; Norleucines
  • Mechanism of Action DNA synthesis inhibitors; Glutamine inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Colorectal cancer
  • Phase I/II Gastric cancer; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours

Most Recent Events

  • 16 Jun 2015 Phase-I/II development is ongoing for metastatic colorectal cancer, renal cell carcinoma, non-small cell lung cancer, gastric cancer and other solid tumours in Europe
  • 26 Feb 2013 New Medical Enzymes terminates a phase II trial in Colorectal cancer (metastatic) in Poland (EudraCT2009-017871-13)
  • 01 Feb 2013 Phase-I/II clinical trials in Gastric cancer in Germany (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top